



# Assessment of the fetal **KEL** genotype from cell-free fetal DNA in maternal blood

Durdova V.<sup>1</sup>, Bohmova J.<sup>2</sup>, Dolezalova T.<sup>1</sup>, Studnickova M.<sup>1</sup>,  
Lubusky M.<sup>1</sup>, Markova I.<sup>2</sup>, Pilka R.<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, University Hospital, Olomouc, Czech Republic

<sup>2</sup>Department of Medical Genetics and Fetal Medicine, University Hospital, Olomouc, Czech Republic

## BACKGROUND

In pregnant women with diagnosed red blood cell alloantibody anti-K (always “K” negative, genotype *k/k*), the fetuses are at risk of hemolytic disease only if the antigen “K” (“K” positive, genotype *k/K*) is present on their erythrocytes. In reality, however, about 95% of the fetuses are “K” negative (genotype *k/k*) and thus are not at risk of hemolytic disease. The clinical importance of assessment of the fetal *KEL* genotype is to exclude “K” negative fetuses (genotype *k/k*) in “K” negative pregnant women. Noninvasive assessment of the fetal *KEL* genotype is not available in the Czech Republic yet.

The *KEL* gene encodes the Kell antigens and is localized on chromosome 7. The coding sequence consists of 19 exons. The *KEL* gene has two major co-dominant alleles, *K* and *k* (*KEL1* and *KEL2*), which are the result of a single nucleotide polymorphism in the 6<sup>th</sup> exon. This single nucleotide change causes the amino acid substitution of Methionine (antigen “K”) for Threonine (antigen “k”). The complementary antigens “K” and “k” thus differ by a single amino acid change.

## OBJECTIVES

Noninvasive assessment of the fetal *KEL* genotype (*k/k* or *k/K*) from cell-free fetal DNA in plasma “K” negative pregnant women (*k/k*).

## MATERIALS AND METHODS

In total, 122 women in the 1<sup>st</sup> trimester of pregnancy (between the 7<sup>th</sup> and the 14<sup>th</sup> gestational week) were tested for the *KEL* genotype from leukocytes of the peripheral blood. 95.1% of these women (116/122) were “K” negative (*k/k*), in which case the test of the fetal *KEL* genotype followed from cell-free fetal DNA in the plasma of the peripheral blood. This was further verified by the buccal smear of the newborns.

Noninvasive assessment of the fetal *KEL* genotype from cell-free fetal DNA in the plasma of pregnant women was carried out through minisequencing by capillary electrophoresis (so called SNaPshot). The assay is based on extending the sequence-specific DNA primer by one base at the site of the *KEL* polymorphism (*K/k*). On the basis of an incorporated, fluorescently marked base, in cases of *KEL* homozygous pregnant women (*k/k* or *K/K*) the additive of the complementary fetal allele (*K* or *k*) can be identified and the fetal *KEL* genotype can be assessed by detecting the fluorescence of the respective base.

## RESULTS

In 97.4% of the “K” negative women (113/116), we were able to assess the fetal *KEL* genotype, which was then verified in newborns. A total of 96.5% fetuses (109/113) were “K” negative (*k/k*), the remaining 3.5% fetuses were “K” positive (*k/K*). Sensitivity and specificity of the method were 100%.

## CONCLUSION

Minisequencing by capillary electrophoresis proved to be a reliable method for assessment of the *K* allele from fetal cell-free DNA in the peripheral blood of a “K” negative pregnant woman (*k/k*).

